Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

10 April 2006

RNAi: A novel antisense technology and its therapeutic potential.

Anne Dallas, Alexander V. Vlassov

Med Sci Monit 2006; 12(4): RA67-74 :: ID: 448934

Abstract

Antisense oligonucleotide agents induce the inhibition of target gene expressionin a sequence-specific manner by exploiting the ability of oligonucleotides to bind to target RNAs viaWatson-Crick hybridization. Once bound, the antisense agent either disables or induces the degradationof the target RNA. This technology may be used for therapeutic purposes, functional genomics, and targetvalidation. There are three major categories of gene-silencing molecules: (1) antisense oligonucleotidederivatives that, depending on their type, recruit RNase H to cleave the target mRNA or inhibit translationby steric hindrance; (2) ribozymes and deoxyribozymes - catalytically active oligonucleotides that causeRNA cleavage; (3) small interfering double-stranded RNA molecules that induce RNA degradation througha natural gene-silencing pathway called RNA interference (RNAi). RNAi is the latest addition to the familyof antisense technologies and has rapidly become the most widely used approach for gene knockdown becauseof its potency. In this mini-review, we introduce the RNAi effect, briefly compare it with existing antisensetechnologies, and discuss its therapeutic potential, focusing on recent animal studies and ongoing clinicaltrials. RNAi may provide new therapeutics for treating viral infections, neurodegenerative diseases,septic shock, macular degeneration, cancer, and other illnesses, although in vivo delivery of small interferingRNAs remains a significant obstacle.

Keywords: Neoplasms - therapy, Neurodegenerative Diseases - therapy, Oligonucleotides, Antisense - genetics, RNA Interference, RNA, Small Interfering - therapeutic use, Virus Diseases - therapy

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750